On June 19, 2018 Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, reported an interim update to shareholders regarding its phase I clinical trial of Cantrixil (TRX-E-002-1) in relapsed or recurrent ovarian cancer (Press release, Kazia Therapeutics, JUN 19, 2018, View Source [SID1234527396]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The phase I study of Cantrixil commenced in December 2016 at five centres in the United States and Australia. It is designed in two parts: a dose escalation component (Part A), which seeks to understand the safety profile of the drug and to determine the maximum tolerated dose (MTD), and a dose expansion cohort (Part B), which seeks to explore initial signals of efficacy. Part A is expected to enroll between 3 and 42 patients, and Part B is expected to enroll 12 patients. The study is registered with clinicaltrials.gov as NCT02903771.
At the present time, the study has enrolled 10 patients in Part A. In general, the drug has encountered few dose-limiting toxicities and, as a result, most dosing cohorts have only required enrolment of a single patient, in line with the trial protocol, which has allowed the study to progress with a number of patients towards the lower extent of the forecast range.
Of the 10 patients recruited to date, 2 were withdrawn from the study prior to receiving treatment, generally on grounds of disease progression, reflecting the severity of this patient population. 3 of 5 patients evaluable for efficacy thus far have achieved ‘stable disease’ (SD) per RECIST criteria after 2 cycles of Cantrixil monotherapy. One patient demonstrated a ‘partial response’ (PR) after receiving Cantrixil in combination with chemotherapy. 3 patients have so far completed the full twenty-four weeks of dosing allowed for in the protocol.
The Data Monitoring Committee has recommended that additional patients should be enrolled to more fully understand the safety profile and to definitively determine the maximum tolerated dose, and the company has therefore continued Part A accordingly. It is now expected that Part A will conclude in the third calendar quarter of 2018, at which time Part B will commence. The Company expects to provide comprehensive data once Part A is complete.
Kazia CEO, Dr James Garner, commented, "We are pleased with the progress of the study to date. Our understanding of both the safety and potential efficacy of Cantrixil will evolve as the study progresses further, and we look forward to sharing additional data as it is determined."